Logo image of ALGBE.PA

GLOBAL BIOENERGIES SA (ALGBE.PA) Stock Fundamental Analysis

EPA:ALGBE - Euronext Paris - Matif - FR0011052257 - Common Stock - Currency: EUR

0.0319  0 (-5.06%)

Fundamental Rating

2

Taking everything into account, ALGBE scores 2 out of 10 in our fundamental rating. ALGBE was compared to 68 industry peers in the Chemicals industry. ALGBE has a bad profitability rating. Also its financial health evaluation is rather negative. ALGBE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALGBE has reported negative net income.
In the past year ALGBE has reported a negative cash flow from operations.
In the past 5 years ALGBE always reported negative net income.
In the past 5 years ALGBE always reported negative operating cash flow.
ALGBE.PA Yearly Net Income VS EBIT VS OCF VS FCFALGBE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of ALGBE (-60.73%) is worse than 92.65% of its industry peers.
The Return On Equity of ALGBE (-346.31%) is worse than 91.18% of its industry peers.
Industry RankSector Rank
ROA -60.73%
ROE -346.31%
ROIC N/A
ROA(3y)-54.57%
ROA(5y)-48.79%
ROE(3y)-195.4%
ROE(5y)-183.82%
ROIC(3y)N/A
ROIC(5y)N/A
ALGBE.PA Yearly ROA, ROE, ROICALGBE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALGBE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGBE.PA Yearly Profit, Operating, Gross MarginsALGBE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

3

2. Health

2.1 Basic Checks

ALGBE does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALGBE has about the same amout of shares outstanding than it did 1 year ago.
ALGBE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALGBE is higher compared to a year ago.
ALGBE.PA Yearly Shares OutstandingALGBE.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALGBE.PA Yearly Total Debt VS Total AssetsALGBE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -2.50, we must say that ALGBE is in the distress zone and has some risk of bankruptcy.
ALGBE's Altman-Z score of -2.50 is on the low side compared to the rest of the industry. ALGBE is outperformed by 89.71% of its industry peers.
A Debt/Equity ratio of 2.78 is on the high side and indicates that ALGBE has dependencies on debt financing.
ALGBE has a worse Debt to Equity ratio (2.78) than 91.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Altman-Z -2.5
ROIC/WACCN/A
WACC5.03%
ALGBE.PA Yearly LT Debt VS Equity VS FCFALGBE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

ALGBE has a Current Ratio of 2.86. This indicates that ALGBE is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.86, ALGBE belongs to the best of the industry, outperforming 83.82% of the companies in the same industry.
ALGBE has a Quick Ratio of 2.73. This indicates that ALGBE is financially healthy and has no problem in meeting its short term obligations.
ALGBE has a Quick ratio of 2.73. This is amongst the best in the industry. ALGBE outperforms 92.65% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.73
ALGBE.PA Yearly Current Assets VS Current LiabilitesALGBE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.31% over the past year.
The Revenue for ALGBE has decreased by -88.90% in the past year. This is quite bad
Measured over the past years, ALGBE shows a very strong growth in Revenue. The Revenue has been growing by 25.15% on average per year.
EPS 1Y (TTM)33.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.52%
Revenue 1Y (TTM)-88.9%
Revenue growth 3Y52.9%
Revenue growth 5Y25.15%
Sales Q2Q%-85.13%

3.2 Future

Based on estimates for the next years, ALGBE will show a decrease in Earnings Per Share. The EPS will decrease by -5.13% on average per year.
Based on estimates for the next years, ALGBE will show a small growth in Revenue. The Revenue will grow by 0.48% on average per year.
EPS Next Y22.81%
EPS Next 2Y-5.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.97%
Revenue Next 2Y0.48%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ALGBE.PA Yearly Revenue VS EstimatesALGBE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
ALGBE.PA Yearly EPS VS EstimatesALGBE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALGBE. In the last year negative earnings were reported.
Also next year ALGBE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGBE.PA Price Earnings VS Forward Price EarningsALGBE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGBE.PA Per share dataALGBE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as ALGBE's earnings are expected to decrease with -5.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.13%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALGBE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLOBAL BIOENERGIES SA

EPA:ALGBE (8/8/2025, 7:00:00 PM)

0.0319

0 (-5.06%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)09-08 2025-09-08
Inst Owners1.07%
Inst Owner ChangeN/A
Ins Owners2.68%
Ins Owner ChangeN/A
Market Cap579.62K
Analysts84.44
Price Target3.37 (10464.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.61
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.02
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.73%
ROE -346.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.57%
ROA(5y)-48.79%
ROE(3y)-195.4%
ROE(5y)-183.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.66%
Cap/Sales 129.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.73
Altman-Z -2.5
F-Score0
WACC5.03%
ROIC/WACCN/A
Cap/Depr(3y)101.02%
Cap/Depr(5y)112%
Cap/Sales(3y)139.76%
Cap/Sales(5y)838.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.52%
EPS Next Y22.81%
EPS Next 2Y-5.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-88.9%
Revenue growth 3Y52.9%
Revenue growth 5Y25.15%
Sales Q2Q%-85.13%
Revenue Next Year0.97%
Revenue Next 2Y0.48%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.13%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.94%
OCF growth 3YN/A
OCF growth 5YN/A